24/7 Wall Street
19 Jun 2026, 19:15 UTC · 2h ago
Prediction: Eli Lilly Will Trade at $1,200 on This Date
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
24/7 Wall Street
19 Jun 2026, 19:15 UTC · 2h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
5 claims · each scored for market impact
Eli Lilly reported 55.5% year-over-year revenue growth to $19.80 billion and raised full-year guidance to $82–$85 billion. — Strong top-line growth and upgraded guidance typically drive significant positive sentiment and price appreciation.
+0.80The oral GLP-1 drug Foundayo showed strong early launch metrics with over 8,000 prescribers and 80% of scripts being new-to-class. — Rapid adoption of a new delivery method (oral) expands the addressable market and competitive advantage.
+0.60Retatrutide's Phase 3 data demonstrated weight loss of 25 to 37 pounds, with results comparable to or exceeding Zepbound. — Positive late-stage trial results for a pipeline drug provide a strong future growth catalyst.
+0.50Continue reading
6 related stories
Top 1 mover · tap to explore
Realized prices for Mounjaro fell 13% in Q1 due to the addition to China's NRDL formulary, compressing international margins. — Price erosion is a primary risk factor that can offset volume gains and dampen profit margins.
-0.40Recent insider transactions have been skewed toward selling. — Concentrated insider selling is often viewed by the market as a bearish signal regarding current valuation.
-0.20Which stocks this story touches
Reported massive revenue growth of 55.5%, raised full-year guidance, and has strong positive projections for Foundayo and retatrutide.
Mentioned briefly as having reported Q1 results alongside Eli Lilly without specific sentiment.
Mentioned only as a historical reference point for an analyst's past success.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
GlobeNewsWire
2h ago
